Roth Capital Downgrades Salix Pharmaceuticals Ltd. (SLXP) to Hold
More News related to SLXP
- Salix Pharmaceuticals Reports 3Q2009 Results
- Trading Radar for 11/09: Dish Network (DISH), Rockwell (ROK), Priceline.com (PCLN), MBIA (MBI), Ticketmaster (TKTM) Report
- Salix Pharmaceuticals to Host Analyst Day on November 18
- Salix Pharmaceuticals to Present at Credit Suisse Conference
- Salix Pharma (SLXP) Announces the Issuance of Two Patents Related to Rifaximin
More News related to Downgrades
- Standpoint Research Downgraded Deckers Outdoor (DECK) to Hold
- BGB Securities Downgrades Helmerich & Payne (HP) to Sell
- Sidoti & Co Downgrades Waste Services (WSII) to Neutral
- William Blair Downgrades Strayer (STRA), ITT (ESI) to Market Perform
- D.A. Davidson Downgrades Rocky Brands (RCKY) to Underperform
Roth Capital downgrades Salix Pharmaceuticals Ltd. (Nasdaq: SLXP) from Buy to Hold with an $8 price target.
Salix Pharmaceuticals, Ltd. develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases in the United States.
Related Categories
DowngradesStocks Mentioned
+0.08Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
